ATLANTA--(BUSINESS WIRE)--June 4, 2006--ImClone Systems Incorporated (NASDAQ: IMCL - News) today announced findings from a Southwest Oncology Group randomized clinical trial (SWOG-0342) of ERBITUX® (Cetuximab), an IgG1 monoclonal antibody, in non-small cell lung cancer. The large, randomized Phase II trial was designed to select an ERBITUX-chemotherapy regimen for future evaluation and subsequent inclusion in a Phase III trial. This study was presented today in an oral session at the American Society of Clinical Oncology (ASCO) 42nd Annual Meeting by Karen Kelly, M.D., Clinical Director of the Thoracic Oncology Program, University of Colorado Cancer Center.
